For Dave Lucchesi, it didn't matter that he was the only male on a dance floor that was otherwise filled with women. Instead, he saw it as a chance to try something new and raise money for a good ...
Novartis has bulked up its cardiology pipeline with a $1.4 billion takeover of Tourmaline Bio and its phase 3-ready drug for atherosclerotic cardiovascular disease (ASCVD). The Swiss pharma group has ...
In a bumper week for new biotech financings, debutante Kardigan ruled the roost with a $300 million first round that will support its vision of developing multiple personalised therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback